A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

@article{Kipnes2010AOS,
  title={A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes},
  author={M. Kipnes and P. Hollander and K. Fujioka and I. Gantz and T. Seck and N. Erondu and Y. Shentu and K. Lu and S. Suryawanshi and M. Chou and A. Johnson-Levonas and S. Heymsfield and D. Shapiro and K. Kaufman and J. Amatruda},
  journal={Diabetes},
  year={2010},
  volume={12}
}
  • M. Kipnes, P. Hollander, +12 authors J. Amatruda
  • Published 2010
  • Medicine
  • Diabetes
  • Aim: To evaluate the efficacy and safety of taranabant in overweight and obese patients with type 2 diabetes mellitus (T2DM). 
    43 Citations

    Paper Mentions

    Interventional Clinical Trial
    A worldwide study with extension in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug for… Expand
    ConditionsObesity Type 2 Diabetes Mellitus, Type 2 Diabetes Mellitus
    InterventionDrug
    The cannabinoid‐1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice
    • 27
    Pharmacotherapies for Obesity: Past, Current, and Future Therapies
    • 202
    • PDF
    Endocannabinoids and obesity.
    • 5

    References

    SHOWING 1-10 OF 72 REFERENCES
    A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin
    • C. Berne
    • Medicine
    • Diabetic medicine : a journal of the British Diabetic Association
    • 2005
    • 90
    Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors?
    • S. Tonstad
    • Medicine
    • Nature Clinical Practice Cardiovascular Medicine
    • 2006
    • 6
    A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study
    • 60
    • PDF
    A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
    • 70
    • PDF
    Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    • 1,324
    • PDF